Lovastatin, Nicotinic Acid, and Rhabdomyolysis
Authors: Peter Reaven, Joseph L. Witztum
Journal: Annals of Internal Medicine (1988)

Letters and Corrections1 October 1988Lovastatin, Nicotinic Acid, and RhabdomyolysisPeter Reaven, MD, Joseph L. Witztum, MDPeter Reaven, MDSearch for more papers by this author, Joseph L. Witztum, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-109-7-597_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor: We recently observed a case of severe rhabdomyolysis in a patient being treated with lovastatin and nicotinic acid. Our report of this case may be both instructive and beneficial to physicians treating patients with hyperlipidemia.In a 43-year-old white man with familial hypercholesterolemia, presumed Gilbert syndrome, and known coronary artery disease, lovastatin therapy was initiated in July 1985. Since August 1986, lovastatin, 40 mg, and colestipol, 10 g, both given twice daily, had been well tolerated. In March 1987, nicotinic acid was started at 200 mg, three times daily, to lower the cholesterol level further. All medications...Reference1. NormanIllingsworthMunsonHsenpud DDJJ. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin [Letter]. N Engl J Med. 1988;318:46-7. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Peter Reaven, MD; Joseph L. Witztum, MDAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byFibratesNicotinic acid and derivativesDietary modulators of statin efficacy in cardiovascular disease and cognitionStatin-induced myopathy: a review and updateStatin myopathy and nutritionRisk Factors and Drug Interactions Predisposing to Statin-Induced MyopathySafety Considerations and Potential Interactions of Vitamins: Should Vitamins Be Considered Drugs?New 2-Aryloxy-3-phenyl-propanoic Acids As Peroxisome Proliferator-Activated Receptors α/γ Dual Agonists with Improved Potency and Reduced Adverse Effects on Skeletal Muscle FunctionLIPID – REGULATING DRUGSToxic MyopathiesNicotinic AcidNiacin in cardiovascular prevention: mechanisms, efficacy, and safetyDose-Dependent Effects of Docosahexaenoic Acid Supplementation on Blood Lipids in Statin-Treated Hyperlipidaemic SubjectsSafety Considerations with Niacin TherapySafety of Lovastatin/Extended Release Niacin Compared With Lovastatin Alone, Atorvastatin Alone, Pravastatin Alone, and Simvastatin Alone (from the United States Food and Drug Administration Adverse Event Reporting System)Toxic and iatrogenic myopathiesManagement of Dyslipidemia in DiabetesStatin Safety: An Overview and Assessment of the Data—2005An Assessment of Statin Safety by Muscle ExpertsEzetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitorNicotinic acid and derivativesFibratesToxic MyopathiesManagement of Diabetic DyslipidemiaARBITER 2: targeting HDL to retard atherosclerosis progressionCombination therapy in the management of complex dyslipidemiasCurrent overview of statin-induced myopathySafety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study)Combination lipid-lowering therapy in diabetesCombination lipid-lowering therapy with statins: safety issues in the postcerivastatin eraTreating Dyslipidemic Patients with Lipid-Modifying and Combination TherapiesA dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatinAntihyperlipidemic AgentsIatrogenic and toxic myopathiesStatins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFALipid-Lowering DrugsAumento de la actividad de la creatincinasa y miopatía por estatinasChapter 32 Toxic myopathiesNiacin-ER and Lovastatin Treatment of Hypercholesterolemia and Mixed DyslipidemiaSafety considerations for statinsFluvastatin-Induced RhabdomyolysisCombination therapy for combined dyslipidemiaCombination therapy for dyslipidemia: safety and regulatory considerationsA safety look at currently available statinsPharmacology of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors (Statins), Including Rosuvastatin and PitavastatinMyopathy and rhabdomyolysis with lipid-lowering drugs3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patientAcquired MyopathiesRhabdomyolysis and Satin Therapy: Relevance to the ElderlyPharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase InhibitorsTyrosine phosphorylation of the catalytic subunit p110 of phosphatidylinositol-3 kinase induced by HMG-CoA reductase inhibitor inhibits its kinase activity in L6 myoblastsRhabdomyolysis and HMG-CoA Reductase InhibitorsInsulin-like Growth Factor-I in Muscle Metabolism and MyotherapiesCARDIOVASCULAR DRUG-DRUG INTERACTIONSSafety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemiaSafety Profiles for the HMG-CoA Reductase InhibitorsNiacin dosing: Relationship to benefits and adverse effectsEffective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial diseasePharmacotherapy of hypercholesterolaemia: statins in clinical practiceLipid-Lowering DrugsNew insights into the pharmacodynamic and pharmacokinetic properties of statinsClinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitorsCombination drug therapy for dyslipidemiaRationale and design of the arterial disease multiple intervention trial (ADMIT) pilot studyLong-Term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemiaTreatment of hyperlipidemia with combined niacin–statin regimensHMG-CoA reductase inhibitor-induced L6 myoblast cell death: involvement of the phosphatidylinositol 3-kinase pathwayShort-term Efficacy and Tolerability of Combination Therapy with Lovastatin and Acipimox in Chinese Patients with Type 2 Diabetes Mellitus and Mixed DyslipidemiaMetabolism and Drug Interactions of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Transplant PatientsAtorvastatin in the Treatment of Primary Hypercholesterolemia and Mixed DyslipidemiasMyopathy Induced by HMG–CoA Reductase Inhibitors in Rabbits: A Pathological, Electrophysiological, and Biochemical StudyEffectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia∗∗See Appendix for list of principal investigators, study sites, and laboratory sites.A comparison of the effects of lovastatin and pravastatin on ubiquinone tissue levels in ratsLong-Term Efficacy and Safety of Fenofibrate and a Statin in the Treatment of Combined HyperlipidemiaLovastatin increases exercise-induced skeletal muscle injuryTOXIC MYOPATHIESModerate Dose, Three-Drug Therapy With Niacin, Lovastatin, and Colestipol to Reduce Low-Density Lipoprotein Cholesterol <100 mg/dl in Patients With Hyperlipidemia and Coronary Artery DiseaseLovastatin-Induced Rhabdomyolysis Possibly Associated with Clarithromycin and AzithromycinLong-term Treatment With Pravastatin Alone and in Combination With Gemfibrozil in Familial Type IIB Hyperlipoproteinemia or Combined HyperlipidemiaDrug Interactions with Agents Used in the Treatment of Cardiovascular DiseaseClinical pharmacologic concepts for the rational selection and use of drugs for the management of dyslipidemiaEffects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cellsDrug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goalsCurrent and Future Therapeutic Approaches to HyperlipidemiaApproaches to The Treatment of Hyperlipidemia in the Solid Organ Transplant RecipientLong-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.Comparative Evaluation of the Safety and Efficacy of HMG-CoA Reductase Inhibitor Monotherapy in the Treatment of Primary HypercholesterolemiaUpdate on the treatment of hypercholesterolemia, with a focus on hmg-coa reductase inhibitors and combination regimensA comparison of the effects of simvastatin and pravastatin monotherapy on muscle histology and permeability in hypercholesterolaemic patients.Heterozygous familial hypercholesterolaemia is associated with pathological exercise-induced leakage of muscle proteins, which is not aggravated by simvastatin therapyThe pharmacology of fluvastatin, a new HMG-CoA reductase inhibitorElectrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitorsFluvastatin with and without niacin for hypercholesterolemiaUpdated clinical safety experience with fluvastatinCombination therapy with fluvastatin and niacin in hypercholesterolemia: A preliminary report on safetyComparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemiaDrugs for treatment of patients with high cholesterol blood levels and other dyslipidemiasEvidence of Plasma CoQ10-Lowering Effect by HMG-CoA Reductase Inhibitors: A Double-Blind, Placebo-Controlled StudyLabetalolEffectiveness of low-dose lovastatin combined with low-dose colestipol in moderate to severe primary hypercholesterolaemiaExperimental simvastatin-induced myopathy in rabbitsGemfibrozil-lovastatin therapy for primary hyperlipoproteinemiasMusculoskeletal Complications After Renal Transplantation: Pathogenesis and TreatmentLovastatin-Induced Rhabdomyolysis in the Absence of Concomitant DrugsHyperlipidemiasRhabdomyolyse causée par la simvastatine chez un transplanté cardiaque sous ciclosporineEffects of exercise and lovastatin on serum creatine kinase activityNicotinic Acid for the Treatment of HyperlipoproteinemiaDrugs in the Management of Lipid DisordersDrugs affecting lipid metabolismRhabdomyolysis and Acute Renal Failure Induced by Combination Lovastatin and Gemfibrozil TherapyGary E. Marais, MB, ChB, Kerry K. Larson, MDLong Term Clinical Tolerance of Lovastatin (Mevinolin) and Simvastatin (Epistatin)Lovastatin and Other HMG-CoA Reductase InhibitorsLOVASTATIN AND ELEVATED CREATINE KINASE: RESULTS OF RECHALLENGELong-Term Management and Late Complications of the Thoracic Organ Transplant Recipient 1 October 1988Volume 109, Issue 7Page: 597-598KeywordsCholesterolFamilial hypercholesterolemiaHyperlipidemiaNiacinRhabdomyolysisStable coronary artery disease ePublished: 1 December 2008 Issue Published: 1 October 1988 PDF downloadLoading ...